Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06947226 | A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 188 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06870279 | A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC | not yet recruiting | Phase 1 | 28 | RenJi HospitalOTHER | 0 | Apr 24, 2025 | clinicaltrials |
| NCT06932094 | Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 | 256 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06934590 | Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC | not yet recruiting | Phase 1 | 18 | GeneCraft Inc.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06941142 | A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer | not yet recruiting | Phase 1 | 382 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 23, 2025 | clinicaltrials |
| NCT06939270 | CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06482307 | Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET([18F]-olaparib) | not yet recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06925659 | A Study of QLM2011 in Subjects With Advanced Solid Tumors | not yet recruiting | Phase 1 | 172 | Qilu Pharmaceutical (Hainan) Co., Ltd.INDUSTRY | 0 | Apr 17, 2025 | clinicaltrials |
| NCT06928363 | A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 212 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 0 | Apr 15, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06913179 | CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma(CAR-T-allo) | not yet recruiting | Phase 1 | 30 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06913192 | Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma(AUTO-CAR-T) | not yet recruiting | Phase 1 | 50 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06913218 | A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC | not yet recruiting | Phase 1 | 60 | AkesoINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06885645 | First-In-Human Study in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | Chengdu Kanghong Biotech Co., Ltd.INDUSTRY | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06906731 | A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 27 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06875791 | Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.(TEMOR) | not yet recruiting | Phase 1 / Phase 2 | 40 | Fundacion Clinica Valle del LiliOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy(PRODIGY-1) | not yet recruiting | Phase 1 / Phase 2 | 500 | CHU de Quebec-Universite LavalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT06788197 | A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | Henan Cancer HospitalOTHER_GOV | 0 | Mar 26, 2025 | clinicaltrials |
| NCT06896396 | Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | Zhiyong HuangOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06896552 | Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC. | not yet recruiting | Phase 1 / Phase 2 | 60 | Rabin Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06894693 | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies | not yet recruiting | Phase 1 | 13 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06775236 | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 410 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT05662904 | Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML(GALAXY33) | not yet recruiting | Phase 1 | 12 | German Cancer Research CenterOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06872580 | A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 149 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06866795 | Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) | not yet recruiting | Phase 1 | 42 | Geode Therapeutics Inc.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06866977 | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 10 | Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06860685 | Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery | not yet recruiting | Phase 1 / Phase 2 | 292 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06846424 | SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | not yet recruiting | Phase 1 | 24 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06845241 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 68 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06827080 | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 15 | Zhengguo ChenOTHER | 0 | Feb 14, 2025 | clinicaltrials |
| NCT05821686 | Efficacy of Interleukin-2 in Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 10 | Nova Scotia Health AuthorityOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06822985 | QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma(QL1706) | not yet recruiting | Phase 1 | 21 | Wan-Guang ZhangOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06823245 | Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function | not yet recruiting | Phase 1 | 32 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06823258 | Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function | not yet recruiting | Phase 1 | 32 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06799676 | A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 42 | Fuling ZhouOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06787950 | Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 200 | Jiangsu Yahong Meditech Co., Ltd aka AsierisINDUSTRY | 0 | Jan 22, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06779045 | A Study of AK-1286 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 50 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jan 16, 2025 | clinicaltrials |
| NCT06770881 | JSKN033 in Chinese Subjects with Advanced Malignant Tumors | not yet recruiting | Phase 1 / Phase 2 | 430 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Jan 13, 2025 | clinicaltrials |
| NCT06760676 | A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy | not yet recruiting | Phase 1 | 90 | Anhui Provincial HospitalOTHER_GOV | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06757335 | A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 204 | Hinova Pharmaceuticals Inc.INDUSTRY | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06757387 | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 45 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06755242 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06752447 | A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors | not yet recruiting | Phase 1 | 94 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 0 | Dec 30, 2024 | clinicaltrials |
| NCT05954091 | OH2 Administered by Intratumoral Injection | not yet recruiting | Phase 1 | 29 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma(EPITOME-1015-I) | not yet recruiting | Phase 1 | 55 | Medigene AGINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746961 | Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy | not yet recruiting | Phase 1 / Phase 2 | 49 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06737146 | Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma | not yet recruiting | Phase 1 | 12 | Suzhou Maximum Bio-tech Co., Ltd.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06584071 | A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | not yet recruiting | Phase 1 / Phase 2 | 140 | Biotheus Inc.INDUSTRY | 0 | Dec 16, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2025source: clinicaltrials